<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01684189</url>
  </required_header>
  <id_info>
    <org_study_id>MISP38887</org_study_id>
    <nct_id>NCT01684189</nct_id>
  </id_info>
  <brief_title>Registry of Febrile Neutropenia and Invasive Fungal Infections</brief_title>
  <official_title>A Non-interventional Prospective Registry to Monitor the Events of Febrile Neutropenia and Invasive Fungal Infections and the Diagnostic and Therapeutic Management in Patients With Malignant Hematologic Diseases After Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives：&#xD;
&#xD;
        1. To assess the percentage of febrile neutropenia and suspected fungal-related febrile&#xD;
           episodes in patients receiving chemotherapy&#xD;
&#xD;
        2. To explore the percentage/distribution of infectious origins of febrile neutropenia&#xD;
&#xD;
        3. To explore the percentage/distribution of infectious pathogens of febrile neutropenia&#xD;
&#xD;
        4. To explore clinical outcomes of different infectious origins/pathogens in febrile&#xD;
           neutropenia episodes&#xD;
&#xD;
        5. To have a clear view of therapeutic actions in the management of hematological patients&#xD;
           with febrile neutropenia and suspected fungal-related febrile episodes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives：&#xD;
&#xD;
        1. To assess the percentage of febrile neutropenia and suspected fungal-related febrile&#xD;
           episodes in patients receiving chemotherapy&#xD;
&#xD;
        2. To explore the percentage/distribution of infectious origins of febrile neutropenia&#xD;
&#xD;
        3. To explore the percentage/distribution of infectious pathogens of febrile neutropenia&#xD;
&#xD;
        4. To explore clinical outcomes of different infectious origins/pathogens in febrile&#xD;
           neutropenia episodes&#xD;
&#xD;
        5. To have a clear view of therapeutic actions in the management of hematological patients&#xD;
           with febrile neutropenia and suspected fungal-related febrile episodes&#xD;
&#xD;
      Study Design：&#xD;
&#xD;
        -  This is a single institute, prospective, non-interventional registry for monitoring&#xD;
           events of febrile neutropenia in hematological patients&#xD;
&#xD;
        -  Patients with newly diagnosed malignant hematological diseases will be enrolled into&#xD;
           this registry&#xD;
&#xD;
      Study Procedures： Data collection will include patients' basic information, underlying&#xD;
      disease, baseline blood chemistry and blood cell counts, antifungal prophylaxis, C/T&#xD;
      regimens, neutrophils and other blood cells, fever diagnosis and infectious sites work-up,&#xD;
      clinical response, microbiology (including bacteria and fungus culture), renal and liver&#xD;
      function, clinical diagnosis, work-up and intensive procedures and results, antifungal and&#xD;
      antibacterial agents (including dosage, duration, and route), other drugs used (including&#xD;
      antivirals, antineoplastics, corticosteroids, immunomodulators), clinical significant changes&#xD;
&#xD;
      Sample Size Calculation and Statistical Analysis： Approximately 100 febrile neutropenia&#xD;
      episodes in 500 chemotherapy cycles will be collected. This is an observational and&#xD;
      exploratory study without hypothesis tests. Study subjects will be collected and monitored&#xD;
      under normal clinical practice, and the sample size will be limited due to the hospital scale&#xD;
      and disease characteristic (the sample size calculation is inapplicable here). All&#xD;
      evaluations will be shown by exploratory and descriptive data analysis. The number of cases&#xD;
      for each investigative definition, the corresponding percentage and the 95% confidence&#xD;
      interval will be described.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hematological Disease</condition>
  <condition>Febrile Neutropenia</condition>
  <condition>Fungal Infections</condition>
  <arm_group>
    <arm_group_label>Patient registry</arm_group_label>
    <description>Patients with newly diagnosed malignant hematological diseases will be enrolled into this registry</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient registry</intervention_name>
    <description>Patient registry without study intervention</description>
    <arm_group_label>Patient registry</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with newly diagnosed malignant hematological diseases&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with new diagnosed hematological diseases (acute and chronic myeloid and&#xD;
             lymphoid leukemia, multiple myeloma, non-Hodgkin's and Hodgkin's lymphoma,&#xD;
             myelodysplastic syndromes)&#xD;
&#xD;
          -  Patients who are receiving chemotherapy and have ongoing febrile episodes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Chung Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming-Chung Wang, M.D.</last_name>
    <phone>+886-7-7317123</phone>
    <phone_ext>3266</phone_ext>
    <email>wang9595@ms32.hinet.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Chung Wang, M.D.</last_name>
      <phone>+886-7-7317123</phone>
      <phone_ext>3266</phone_ext>
      <email>wang9595@ms32.hinet.net</email>
    </contact>
    <investigator>
      <last_name>Ming-Chung Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>September 10, 2012</study_first_submitted>
  <study_first_submitted_qc>September 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2012</study_first_posted>
  <last_update_submitted>September 11, 2012</last_update_submitted>
  <last_update_submitted_qc>September 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

